CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of US$719 million for the six months ended 31 December 2015, up US$27 million or 4% on a reported basis when compared to the prior comparable period (PCP). Earnings per share (EPS) grew 9%. After excluding financials relating to the recently acquired Novartis influenza vaccines business, underlying1NPAT grew 7% and EPS grew 12%, at constant currency2.
HIGHLIGHTS
Financial
-
Sales US$3,056 million, up 11% on PCP
Underlying1 sales up 9% at constant currency2 -
NPAT US$719 million, up 4% on PCP
Underlying NPAT up 7% at constant currency -
Earnings per share US$1.55, up 9% on PCP
Underlying EPS up 12% at constant currency -
Cashflow from operations US$705 million, up 8% on PCP
Interim dividend3 of US$0.58 per share, unfranked for Australian tax purposes, payable on 15 April 2016
Converted to Australian currency, the interim dividend increased to approximately A$0.81 per share, up ~10% on PCP.
Download this release: 
CSL Half Year Result Announcement for 2015/16(0.2Mb)
Additional resources:
Details about CSL's results are included in the company's 4E statement, investor presentation slides and webcast. More ...
For further information, please contact:
|
Investors: Mark Dehring Head of Investor Relations CSL Limited Phone: +613 9389 3407 Email: [email protected] |
Media: Sharon McHale Senior Director Public Affairs CSL Limited Phone: +613 9389 3425 Mobile: +614 0997 8314 Email: [email protected] |